Nasal spray mak­er clinch­es first PhI­II win it needs to reach a much, much big­ger mar­ket

Four and a half years af­ter first go­ing pub­lic on the promise of build­ing out a fran­chise for its nasal spray, Opti­nose says it has the land­mark Phase III da­ta to fi­nal­ly move for­ward.

The Yard­ley, PA-based biotech is re­port­ing pos­i­tive topline re­sults from Re­Open1, sug­gest­ing that pa­tients with chron­ic si­nusi­tis would im­prove af­ter us­ing XHANCE, an “ex­ha­la­tion” de­vice that de­liv­ers a cor­ti­cos­teroid named flu­ti­ca­s­one.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER